We are live on ! Find out more
IMMX icon

Immix Biopharma

31 hedge funds and large institutions have $5.78M invested in Immix Biopharma in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

35% more funds holding

Funds holding: 2331 (+8)

23% more capital invested

Capital invested by funds: $4.68M → $5.78M (+$1.1M)

1.48% more ownership

Funds ownership: 8.11%9.59% (+1.5%)

Holders
31
Holders Change
+8
Holders Change %
+34.78%
% of All Funds
0.41%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
7
Reduced
4
Closed
4
Calls
Puts
Net Calls
Net Calls Change

IMMX Hedge Fund Activity: Q3 2025 in Review

31 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q3 2025, worth a combined $5.78M — up 23% from $4.68M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new IMMX positions and 4 closed out — a net gain of 8 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $215K. The largest seller was Virtu Financial, exiting entirely with an estimated $37K sold.

  • 31 institutional investors held Immix Biopharma (IMMX) as of Q3 2025, up from 23 in Q2 2025.
  • Funds reported $5.78M of Immix Biopharma stock for Q3 2025, up 23% quarter-over-quarter.
  • 12 funds opened new Immix Biopharma positions in Q3 2025 and 4 closed out, a net change of +8 holders.
  • The largest Immix Biopharma buyer in Q3 2025 was Citadel Advisors, an estimated $215K added.
  • The largest Immix Biopharma seller in Q3 2025 was Virtu Financial, an estimated $37K sold.

Based on aggregated 13F filings for Q3 2025.